Inactivation of the p53 function is a common event in cancer. Approx. 50% of human tumours express mutant p53 and there is evidence that in others, including many childhood tumours, p53 function is impaired in other ways. These defects on p53 function may be due to the alteration of cellular factors that modulate p53 or to the expression of viral oncoproteins. Radiotherapy and many of the chemotherapeutic drugs currently used in cancer treatment are potent activators of p53. However, most of these therapies have a serious drawback; that is, the long-term consequences of their DNA-damaging effects. Understanding the mechanisms regulating p53 stability is crucial for the development of new strategies to activate p53 non-genotoxically. Here we describe the effect of a potent activator of the p53 response, the nuclear export inhibitor leptomycin B, on Mdm2 degradation and we provide evidence for the oligomerization of the p14ARF tumour suppressor and Mdm2 inhibitor in response to oxidative stress.
Conference Article| April 01 2003
Protecting p53 from degradation
Biochem Soc Trans (2003) 31 (2): 482-485.
- Views Icon Views
- Share Icon Share
- Cite Icon Cite
S. Laín; Protecting p53 from degradation. Biochem Soc Trans 1 April 2003; 31 (2): 482–485. doi: https://doi.org/10.1042/bst0310482
Download citation file: